Deciphera Pharmaceuticals has filed for FDA approval of ripretinib in patients with advanced gastrointestinal stromal tumors. The filing moves Deciphera closer to establishing ripretinib as an option for patients failed by drugs from Bayer, Novartis and Pfizer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,